BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Mol Cancer 2019;18:154. [PMID: 31684964 DOI: 10.1186/s12943-019-1092-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 Vardam-Kaur T, Pathangey LB, McCormick DJ, Bergsagel PL, Cohen PA, Gendler SJ. Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma. Oncotarget 2021;12:2051-67. [PMID: 34611479 DOI: 10.18632/oncotarget.28067] [Reference Citation Analysis]
2 Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol 2020;13:29. [PMID: 32245497 DOI: 10.1186/s13045-020-00862-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
3 van der Schans JJ, van de Donk NWCJ, Mutis T. Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. Front Oncol 2020;10:1362. [PMID: 32850436 DOI: 10.3389/fonc.2020.01362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
4 Du M, Hari P, Hu Y, Mei H. Biomarkers in individualized management of chimeric antigen receptor T cell therapy. Biomark Res 2020;8:13. [PMID: 32426136 DOI: 10.1186/s40364-020-00190-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
5 Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res 2020;26:6028-38. [PMID: 32917735 DOI: 10.1158/1078-0432.CCR-20-0400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Page A, Fusil F, Cosset FL. Towards Physiologically and Tightly Regulated Vectored Antibody Therapies. Cancers (Basel) 2020;12:E962. [PMID: 32295072 DOI: 10.3390/cancers12040962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Ebrahimiyan H, Tamimi A, Shokoohian B, Minaei N, Memarnejadian A, Hossein-Khannazer N, Hassan M, Vosough M. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Int Immunopharmacol 2022;106:108587. [PMID: 35149294 DOI: 10.1016/j.intimp.2022.108587] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Ho M, Goh CY, Patel A, Staunton S, O'Connor R, Godeau M, Bianchi G. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clin Lymphoma Myeloma Leuk 2020;20:e752-68. [PMID: 32651110 DOI: 10.1016/j.clml.2020.05.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 El-Khazragy N, Ghozy S, Emad P, Mourad M, Razza D, Farouk YK, Mohamed NA, Ahmed MK, Youssef T, Bahnasawy YM, Elmasery S. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. Immunotherapy 2020;12:1341-57. [PMID: 33148070 DOI: 10.2217/imt-2020-0181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 García-Guerrero E, Sierro-Martínez B, Pérez-Simón JA. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. Front Immunol 2020;11:1128. [PMID: 32582204 DOI: 10.3389/fimmu.2020.01128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Gao Y, Wang Y, Luo F, Chu Y. Optimization of T Cell Redirecting Strategies: Obtaining Inspirations From Natural Process of T Cell Activation. Front Immunol 2021;12:664329. [PMID: 33981310 DOI: 10.3389/fimmu.2021.664329] [Reference Citation Analysis]
12 Yamahira S, Heike Y. Facile Fabrication of Thin-Bottom Round-Well Plates Using the Deformation of PDMS Molds and Their Application for Single-Cell PCR. Micromachines (Basel) 2020;11:E748. [PMID: 32751967 DOI: 10.3390/mi11080748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Menè P, De Alexandris L, Moioli A, Raffa S, Stoppacciaro A. Monoclonal Gammopathies of Renal Significance: Renal Biopsy and Beyond. Cancers (Basel) 2020;12:E1741. [PMID: 32629844 DOI: 10.3390/cancers12071741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Kaloyannidis P, Apostolidis J. Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure? Curr Treat Options Oncol 2021;22:65. [PMID: 34110512 DOI: 10.1007/s11864-021-00864-x] [Reference Citation Analysis]
15 Kampa M, Notas G, Stathopoulos EN, Tsapis A, Castanas E. The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer. Front Oncol 2020;10:827. [PMID: 32612943 DOI: 10.3389/fonc.2020.00827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 McMillan A, Warcel D, Popat R. Antibody-drug conjugates for multiple myeloma. Expert Opin Biol Ther 2021;21:889-901. [PMID: 32729730 DOI: 10.1080/14712598.2020.1802422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 Padda J, Khalid K, Zubair U, Peethala MM, Kakani V, Goriparthi L, Almanie AH, Cooper AC, Jean-Charles G. Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma. Cureus 2021;13:e15917. [PMID: 34322356 DOI: 10.7759/cureus.15917] [Reference Citation Analysis]
18 Giuliani M, Poggi A. Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. Cells 2020;9:E1578. [PMID: 32610578 DOI: 10.3390/cells9071578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ishibashi M, Morita R, Tamura H. Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma. Cancers (Basel) 2021;13:E279. [PMID: 33451089 DOI: 10.3390/cancers13020279] [Reference Citation Analysis]
20 Zhou X, Rasche L, Kortüm KM, Danhof S, Hudecek M, Einsele H. Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. Front Immunol 2020;11:620312. [PMID: 33424871 DOI: 10.3389/fimmu.2020.620312] [Reference Citation Analysis]
21 Holthof LC, Mutis T. Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance. Cancers (Basel) 2020;12:E988. [PMID: 32316450 DOI: 10.3390/cancers12040988] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
22 Lassiter G, Bergeron C, Guedry R, Cucarola J, Kaye AM, Cornett EM, Kaye AD, Varrassi G, Viswanath O, Urits I. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Curr Oncol 2021;28:640-60. [PMID: 33494319 DOI: 10.3390/curroncol28010063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Alard E, Butnariu AB, Grillo M, Kirkham C, Zinovkin DA, Newnham L, Macciochi J, Pranjol MZI. Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. Cancers (Basel) 2020;12:E1826. [PMID: 32645977 DOI: 10.3390/cancers12071826] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
24 Peaytt R, Parsons LB, Siler D, Matthews R, Li B, Bell D, Bachier C, Pantin J, Berdeja J, Flinn I, Donnellan W, Battiwalla M. The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy. J Oncol Pharm Pract 2021;:10781552211052635. [PMID: 34816754 DOI: 10.1177/10781552211052635] [Reference Citation Analysis]
25 Camp FA, Slansky JE. Implications of Antigen Selection on T Cell-Based Immunotherapy. Pharmaceuticals (Basel) 2021;14:993. [PMID: 34681217 DOI: 10.3390/ph14100993] [Reference Citation Analysis]
26 Zhang L, Shen X, Yu W, Li J, Zhang J, Zhang R, Li J, Chen L. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Ann Med 2021;53:1547-59. [PMID: 34459681 DOI: 10.1080/07853890.2021.1970218] [Reference Citation Analysis]
27 Buller CW, Mathew PA, Mathew SO. Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. Cancers (Basel) 2020;12:E1755. [PMID: 32630303 DOI: 10.3390/cancers12071755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
28 Quazi S. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy. Clin Lymphoma Myeloma Leuk 2022;22:e392-404. [PMID: 34992008 DOI: 10.1016/j.clml.2021.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Mendoza-Reinoso V, McCauley LK, Fournier PGJ. Contribution of Macrophages and T Cells in Skeletal Metastasis. Cancers (Basel) 2020;12:E1014. [PMID: 32326073 DOI: 10.3390/cancers12041014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
30 Liu H, Pan C, Song W, Liu D, Li Z, Zheng L. Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomark Res 2021;9:62. [PMID: 34332618 DOI: 10.1186/s40364-021-00316-6] [Reference Citation Analysis]
31 Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 2021;11:69. [PMID: 33824268 DOI: 10.1038/s41408-021-00459-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
32 Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. Int J Med Sci 2021;18:1786-97. [PMID: 33746596 DOI: 10.7150/ijms.46811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Menè P, Moioli A, Stoppacciaro A, Lai S, Festuccia F. Acute Kidney Injury in Monoclonal Gammopathies. J Clin Med 2021;10:3871. [PMID: 34501317 DOI: 10.3390/jcm10173871] [Reference Citation Analysis]
34 Lim FLWI, Ang SO. Emerging CAR landscape for cancer immunotherapy. Biochem Pharmacol 2020;178:114051. [PMID: 32446888 DOI: 10.1016/j.bcp.2020.114051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J 2021;11:84. [PMID: 33927192 DOI: 10.1038/s41408-021-00469-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
36 Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 2020;13:125. [PMID: 32943087 DOI: 10.1186/s13045-020-00962-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
37 Shao C, Anand V, Andreeff M, Battula VL. Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer. Ann N Y Acad Sci 2021. [PMID: 34596246 DOI: 10.1111/nyas.14700] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 LeBlanc MR, LeBlanc TW, Leak Bryant A, Pollak KI, Bailey DE, Smith SK. A Qualitative Study of the Experiences of Living With Multiple Myeloma. Oncol Nurs Forum 2021;48:151-60. [PMID: 33600390 DOI: 10.1188/21.ONF.151-160] [Reference Citation Analysis]
39 Xiao BF, Zhang JT, Zhu YG, Cui XR, Lu ZM, Yu BT, Wu N. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Front Immunol 2021;12:782775. [PMID: 34790207 DOI: 10.3389/fimmu.2021.782775] [Reference Citation Analysis]
40 Abramson HN. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci 2020;21:E5192. [PMID: 32707894 DOI: 10.3390/ijms21155192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
41 Richter J, Ramasamy K, Rasche L, Bladé J, Zweegman S, Davies F, Dimopoulos M. Management of patients with difficult-to-treat multiple myeloma. Future Oncol 2021;17:2089-105. [PMID: 33706558 DOI: 10.2217/fon-2020-1280] [Reference Citation Analysis]
42 Li YR, Zhou Y, Kramer A, Yang L. Engineering stem cells for cancer immunotherapy. Trends Cancer 2021:S2405-8033(21)00171-0. [PMID: 34479851 DOI: 10.1016/j.trecan.2021.08.004] [Reference Citation Analysis]
43 Jeske AM, Boucher P, Curiel DT, Voss JE. Vector Strategies to Actualize B Cell-Based Gene Therapies. J Immunol 2021;207:755-64. [PMID: 34321286 DOI: 10.4049/jimmunol.2100340] [Reference Citation Analysis]
44 Cronk RJ, Zurko J, Shah NN. Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. Cancers (Basel) 2020;12:E2523. [PMID: 32899464 DOI: 10.3390/cancers12092523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol 2021;14:66. [PMID: 33879198 DOI: 10.1186/s13045-021-01077-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]